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Learning 
objectives 
After completing this module students should:  
• know what screenings are, what are their benefits and 
disadvantages, as well as key issues in screening; 
• be aware of ethical problems of screenings; 
• be able to list most important recommended screenings in 
Europe in different age groups; 
• be familiar with breast cancer screening process. 
Abstract There have been various definitions of screening over the years, but 
simply what we are talking about in screening is seeking to identify a 
disease or pre-disease condition in apparently healthy individuals. 
This concept is now widely accepted in most of the developed word. 
Used wisely, it can be a powerful tool in the prevention of a disease. 
Screening has important ethical differences from clinical practice 
as the health service is targeting apparently healthy people, offering 
to help individuals to make better informed choices about their 
health. 
The module is presenting basic theoretical background necessary 
for understanding the usefulness of screenings, the screening process, 
and potential risks, as well as it provides a case study of breastt cancer 
screening. 
Teaching 
methods 
An introductory lecture gives the students first insight in 
characteristics of screenings. The theoretical knowledge is 
illustrated by a case study. 
After introductory lectures students first carefully read the 
recommended readings. Afterwards they discuss the characteristics 
of screenings, their benefits and disadvantages, as well as key 
issues in screening. They also discuss the basic criteria to be 
fulfilled before screening for any condition is introduced. 
In continuation, they are supposed to be more deeply engaged 
in breast cancer screening process. 
Specific 
recommendation
s 
for teachers 
• work under teacher supervision/individual students’ work 
proportion: 30%/70%; 
• facilities: a computer room; 
• equipment: computers (1 computer on 2-3 students), LCD 
projection equipment, internet connection, access to the 
bibliographic data-bases; 
• training materials: recommended readings or other related 
readings; 
• target audience: master degree students according to Bologna 
scheme. 
Assessment of 
students 
Multiple choice questionnaires. 
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THEORETICAL BACKGROUND 
Basic definitions and explanations of terms 
Screening 
According to the National Screening Committee of the United Kingdom Health 
Departments Second Report (1, 2), screening is a public health service in which members 
of a defined population, who do not necessarily perceive they are at risk of, or are already 
affected by a disease or its complications, are asked a question or offered a test, to identify 
those individuals who are more likely to be helped than harmed by further tests or 
treatment to reduce the risk of a disease or its complications.  
There have been various definitions of screening over the years (1,3-5) but put 
simply what we are talking about in screening is seeking to identify a disease or pre-
disease condition in apparently healthy individuals. This concept is now widely accepted in 
most of the developed word. When used wisely, it can be a powerful tool in the prevention 
of a disease. 
Screening has important ethical differences from clinical practice. The health service 
is targeting apparently healthy people, offering to help individuals to make better informed 
decisions about their health. Irrespective that screening has the potential to save lives or 
improve quality of life through early diagnosis of serious conditions it is not a fool-proof 
process. Screening can reduce the risk of developing a condition or its complications but it 
cannot offer a guarantee of protection. In any screening programme, there is an irreducible 
minimum of false positive results (wrongly reported as having the condition) and false 
negative results (wrongly reported as not having the condition). 
 
Screening programmes 
Screening programmes are public health services that are organized at the level of a large 
population and must be effectively monitored. Programmes must use research evidence to 
identify that they do more good than harm at a reasonable cost. Proposed new screening 
programmes should be assessed against a set of internationally recognised criteria. These 
criteria include the epidemiology of the condition, the screening test, any treatment options, 
and the acceptability of the screening programme. 
The benefits of screening for disease prevention were first demonstrated in the 
1940s, by the use of mass miniature radiography (MMR) for the identification of 
individuals with tuberculosis (TB). After the end of the Second World War, when 
effective treatment for TB was introduced, the use of MMR became widespread in 
many western countries. In 1968, WHO issued monograph Principles and Practice of 
Screening for Disease (5), which remains a landmark contribution to the screening 
literature. 
 
Types of screening 
It is important to distinguish between two main types of screening, being organized 
screening, and opportunistic screening. Their main characteristics are as follows (1, 6-8):  
• organized screening is a process in which people thought to be at risk are invited for 
screening inside organized screening programme, as in the national programmes for 
cancer of the breast and cervix for example. It takes place in a community setting .It 
could be checked and monitored; 
• in contrast, opportunistic screening is screening offered by a medical doctor or other 
health professional outside an organized screening programme. Unlike an organised 
screening programme, opportunistic screening may not be checked or monitored. 
 
Screening need to be distinguished from case-finding, where individuals have sought 
medical advice for a specific symptom or complaint and opportunity is taken to suggest 
various other tests, such as the measurement of blood pressure or cholesterol, appropriate 
to their age and sex (3, 8). It takes place in a clinical setting. 
 
 
Criteria for screening 
Before screening for any condition is introduced, the basic criteria have to be fulfilled 
(Table 1) (5). They are fundamental to the integrity of the screening process in any 
country. 
 
Table 1. Summary of criteria for screening (5). 
Category Criteria 
Condition 
 
The condition sought should be an important health 
problem whose natural history, including 
development from latent to declared disease, is 
adequately understood. The condition should have a 
detectable preclinical phase. 
Target 
population 
There should be a defined target population. 
Diagnosis There should be a suitable diagnostic test that is 
available, safe and acceptable to the population 
concerned. There should be an agreed policy, based 
on respectable test findings and national standards, 
as to whom to regard as patients, and the whole 
process should be a continuing one. 
Treatment There should be an accepted and established 
treatment or intervention for individuals identified 
as having the disease or pre-disease condition and 
facilities for treatment should be available. 
Cost The cost of case-finding (including diagnosis and 
treatment) should be economically balanced in 
relation to possible expenditure on medical care as a 
whole. 
Screening 
test 
Should be acceptable and safe. 
 
The validity of screening test and the evaluation of screening 
Validity 
Validity of screening tests is an expression of a degree to which a test measures what it 
intends to measure (3). There are two measures to describe the validity of screening test – 
sensitivity and specificity. Both measures are conditional probabilities, and both are easy to 
understand using a decision matrix (Figure 1) (6).  
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Figure 1. Decision matrix for derivation of the validity analysis of a screening test. 
 
 
1. Sensitivity. 
Sensitivity (nosological) is defined as the ability of a test to detect all those with the 
disease in the screened population. This is expressed as the proportion of those with the 
disease in whom a screening test gives a positive result. Technically, it is a proportion of 
people with condition with positive test: a/(a+c) (Table 2). 
2. Specificity. 
Specificity is defined as the ability of a test to identify correctly those free of the disease 
in the screened population. This is expressed as a proportion of people free of the disease 
in whom the screening test gives a negative result. Technically, it is a proportion of 
people without condition with negative test: a/(a+c) (Table 2). 
 
But one should be aware interpreting these measures since there are two kinds of 
sensitivity and specificity - nozological and diagnostic (9,10). So far we were speaking of 
nosological conditional probabilities. Other two important conditional probabilities are 
positive and negative predictive values (9,11). 
3. Positive predictive value. 
Positive predictive value is the probability that a person with a negative test does not 
have the condition under screening. Technically, it is a proportion of people with 
positive test who have condition: a/(a+b) (Table 2). This measure is also known as 
diagnostic specificity. 
4. Negative predictive value. 
Negative predictive value is the probability that a person with a negative test does 
not have the condition under screening. Technically, it is a proportion of people with 
negative test who do not have condition: d/(c+d) (Table 2). This measure is also 
known as diagnostic sensitivity. 
 
All screening tests should aim to have high sensitivity and high specificity. 
 
Evaluation 
Evaluation must also be an integral part of any screening procedure. In 1971, Cochrane and 
Holland suggested seven criteria for evaluation and these remain as valid today as they 
were then (12) (Table 2).  
 
Table 2. Summary of criteria for evaluation of screening (12). 
Factor Criteria 
Simplicity The test should be simple to perform, easy to interpret 
and, where possible, capable of use by paramedics and 
other personnel. 
Acceptability Since participation in screening is voluntary, the test 
must be acceptable to those undergoing it. 
Accuracy The test must give a true measurement of the condition 
or symptom under investigation. 
Cost The expense of the test must be considered in relation 
to the benefits of early detection of the disease. 
Repeatability The test should give consistent results in repeated 
trials. 
Sensitivity The test should be capable of giving a positive finding 
when the individual being screened has the condition 
being sought. 
Specificity The test should be capable of giving a negative finding 
when the individual being screened does not have the 
condition being sought. 
 
 
Benefits and disadvantages 
The benefits and disadvantages of screening have been fully described over the years and 
have been summarized by Chamberlain (13) (Table 3). 
 
Table 3. Benefits and disadvantages of screening (13). 
Benefits Disadvantages 
Improved prognosis for cases 
detected 
Longer morbidity in cases where 
prognosis is unaltered 
Less radical treatment which 
cures some early cases 
Overtreatment of questionable 
abnormalities 
Resource savings Resource costs 
Reassurance for those with 
negative test results 
False reassurance for those with 
false-negative results 
Anxiety and sometimes morbidity for 
those with false positive results 
Hazard of screening test itself 
 
 1. Benefits. 
The benefits are very clear. Early and accurate diagnosis and intervention will lead to 
an improved prognosis in some patients. At this stage treatment may need to be less 
invasive.  
2. Disadvantages. 
The disadvantages are more complex. There will be longer periods of morbidity for 
patients whose prognosis is unchanged and there may be overtreatment of non-serious 
conditions or abnormalities identified. There are also resource costs in finding more 
illness both in terms of the tests themselves, the personnel costs and the subsequent 
management of whatever is found. There is the unpalatable certainty that some 
individuals with false-negative results will be given unfounded reassurance and that 
some with false positive results will experience, at the very least, unnecessary anxiety 
and, at the worst, inappropriate treatment.  
 
Finally, there is the possibility, however remote, of hazard from the screening test itself. 
One point is particularly relevant here - there may be public demand (fuelled by vested 
interests) for the introduction of a screening test that does not meet the established criteria; 
an example of this is in screening for cancer of the prostate where the current screening test 
– prostate-specific antigen (PSA) – does not meet the criteria for accuracy or specificity. 
 
 
Key issues in screening 
There are a number of issues that are relevant at all stages and in every type of screening 
programme in any country, and are closely interrelated. There are five key issues in 
screening, being genetics, information, economics, ethics, and audit, evaluation and 
quality control (Figure 2). 
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Figure 2. Five key issues of screening. 
 
 
Before discussing the above mentioned key issues, one should consider 
components of an effectively organized screening programme. The components as 
described by Hakama (14) are as follows: 
• the target population should be identified; 
• individuals in the population who are to be screened need to be identified; 
• all those eligible for screening should be encouraged to attend – for example, by 
issuing a personal invitation, and offering suitable timing of screening 
examinations to suit the needs of those involved; 
 • there should be adequate premises, equipment and staff to ensure that the screening 
examination is done under pleasant circumstances and is acceptable to those 
attending; 
• there should be an appropriate, satisfactory method of ensuring the maintenance of 
the best standards of the test(s) by: 
− initial and continuing training of the personnel conducting the test(s); 
− demonstration (by appropriate records) of the maintenance standards of 
equipment used in the examination – for example, calibration of X-ray 
machines in mammography; 
− routine checks of the validity of the tests performed – for example, random 
duplicate measurements for biochemistry, cytology, and reading of X-rays; 
• there should be adequate and appropriate facilities for the diagnosis and treatment 
of any individual found to require this. There should be as little delay as possible 
between the screening attendance, advice that the screening test was negative, 
advice that the screening test result required further investigation, and referral to 
the appropriate centre for further investigation or treatment. A timetable should be 
established for these different procedures and there should be continuous 
monitoring to ensure that the time intervals between the various stages are 
complied with; 
• there should be regular checks to ascertain the satisfaction level of those who have 
undergone the screening process – those investigated, the screen-negatives and 
those invited who have not participated; 
• finally, regular periodic checks should be made of the records of the screened 
individuals to ascertain their adequacy. 
 
 
Genetics 
In the last decade, genetic screening has developed very rapidly with the mapping of the 
human genome. Many see it as opening up a new era in the prevention, early diagnosis 
and identification of disease. However, caution is essential (4). 
There are two objectives of screening for a recessive carrier state. One is to reduce 
the prevalence of the disorder and the other is to inform the reproductive choices of 
individuals and couples at risk. Information is thus regarded as worthwhile in itself, 
regardless of the possibility of prevention or treatment. While this type of screening can 
certainly help to evaluate risk and may be appropriate in certain high-risk groups. It 
should be carefully considered when to screen, if nothing can be done after the results of 
the screening test (4). 
The main purpose of genetic screening at present is to prevent. In this it differs 
from much current screening practice and it must not be allowed to overlook the basic 
principles and criteria of screening (4). 
 
Information 
Information is another central concept in modern health care in general and also in 
screening. It must be provided in a correct way, so that possible participant may decide 
upon proper information, with the end-point being truly informed consent (or refusal) to 
participate (4). 
 
Economics 
As economic theory has entered the field, it has been recognized that screening may also 
do harm. All screening procedures involve the examination and testing of large numbers 
of individuals in order to find the few with an abnormality. There are two main 
consequences of this (4).  
First, those who undergo screening are often understandably anxious while waiting 
for the result and become even more anxious if they have to undergo further 
investigation. Second, although most screening tests are simple, relatively cheap 
procedures in themselves, the actual costs are by no means trivial because of the large 
numbers involved (4). 
 
Ethics 
Any abnormality identified, whether in a national screening programme or in primary 
care, must be treatable and the investigation itself must not cause harm. Many believe 
that early diagnosis, particularly of cancer and heart disease, will lead to the possibility 
of treatment and improvement in prognosis. This is an attractive concept and can lead to 
a demand for a screening procedure to be introduced, irrespective of whether it has been 
shown that diagnosis guarantees an improved outcome (4). 
 
Audit, evaluation and quality control 
In any screening programme, as with any other service programme, adequate steps must 
be taken to ensure that the original objectives are being met and that the methodology 
meets appropriate standards (4). 
The ideal method for evaluating a screening programme is the randomized controlled 
trial in which individuals in a population are allocated, at random, either to a group that is 
screened or to a group that receives only its normal medical care (4). 
The components of an effectively organized screening programme have been 
described by Hakama (14), and have been already presented earlier in this module. 
The importance of maintaining the quality of screening programmes should never 
be underestimated. Evaluation, audit and quality control should be an integral part of any 
screening programme to ensure that it is achieving what it has set out to do in a way that 
is acceptable to those involved. 
 
 
The recommended screenings in Europe 
There are several recommended screenings in Europe (4). They may be presented 
through different age groups, being: 
• antenatal period; 
• neonatal period; 
• screening in childhood; 
• screening in adolescence and early adulthood; 
• screening in adults, and 
• screening in elderly. 
 
 Recommended screenings by age groups 
1. Antenatal period. 
There are many routine screenings for the total population, and some screenings for 
high risk groups (Table 5). There are also some screenings under research review 
(Table 4) (4, 14). 
 
Table 4. Recommended screenings in antenatal period in Europe (4) 
Condition under screening Comment 
Routine 
Anaemia Blood test 
Blood group and RhD status  
Hepatitis B  
HIV  
Risk factors for pre-eclampsia  
Rubella immunity  
Syphilis  
  
Asymptomatic bacteriuria Urine test 
  
Foetal anomalies: Anencephaly Ultrasound, and blood test if indicated 
Spina bifida  
  
Chromosome abnormalities: Down 
syndrome 
Quadruple serum test, ultrasound 
High risk only 
Thalassaemia/sickle cell disease  
Tay-Sachs disease  
Under research review 
Duchenne muscular dystrophy  
Chlamydia infection  
Gestational diabetes  
Fragile X syndrome  
Hepatitis C  
Genital herpes  
HTLV1  
Streptococcus B infection  
 
 
2. Neonatal period. 
There are many routine screenings, and some screenings under research review 
(Table 5). 
 
 
3. Childhood. 
Screenings, recommended in Europe in the childhood are presented in Table 6. 
Table 5. Recommended screenings in neonatal period in Europe (4) 
Condition under screening Comment 
Routine 
Phenylketonuria Bloodspot 
Congenital hypothyroidism  
Cystic fibrosis  
Sickle cell disease  
  
Congenital heart disease Physical examination 
Congenital cataract  
Cryptorchism  
Congenital dislocation of the hip/  
        developmental dysplasia of the hip test  
Other congenital malformations  
  
Hearing impairment  
Under research review 
Biotinidase deficiency  
Congenital adrenal hyperplasia  
Duchenne muscular dystrophya  
 
 
Table 6. Recommended screenings in childhood in Europe (4) 
Condition under 
screening 
Comment 
Hearing impairment • Follow-up on neonatal programme where indicated 
• School entry “sweep” test to continue 
• Case-finding to identify late onset or progressive impairment 
• Investigation of any children with educational or behavioural 
problems 
Amblyopia and 
impaired vision 
• Orthoptist screening in 4–5-year-olds 
• Attention to be paid to children who miss this test for any 
reason 
Dental disease • School dental screening mandatory and should continue, but 
should be kept under research review 
• Early contact with dentists to be encouraged 
• Problems include shortage of dentists and lack of parental 
compliance, especially among the more deprived 
Congenital hip 
dysplasia/ 
developmental dysplasia 
of the hip (CHD/DDH)  
• Children identified by neonatal screening to be reviewed 
• Parental observations and concerns to be investigated 
Deprived, disadvantaged 
or socially isolated 
children 
• Need to identify such children and instigate screening/case-
finding where relevant 
 4. Adolescence and early adulthood. 
Screenings, recommended in Europe in adolescence and early adulthood are 
presented in Table 7. 
 
Table 7. Recommended screenings in adolescence and early adulthood in Europe (4) 
Condition under screening Comment 
Chlamydia • Opportunistic screening of those aged 25 and under 
who access sexual health services or primary care 
 
 
5. Adults. 
In Table 8, screenings, recommended in Europe in adulthood are presented. 
 
Table 8. Recommended screenings in adulthood in Europe (4) 
Condition under screening Comment 
Breast cancer • National programme should be continued but kept 
under close review with emphasis on quality control, 
staff training and good information 
Cervical cancer • National programme should be continued with 
review of alternative types of tests and of age range 
of those eligible and frequency of screening, 
• Good information to be a priority 
Colorectal cancer • National screening programme by faecal occult 
blood testing for adults aged 50–74 years 
Abdominal aortic • Ultrasound screening of men aged 65 and over 
Aneurysm seems a reasonable proposition provided 
the necessary resources are in place 
Diabetic retinopathy • National programme of screening for all diabetics 
aged over 12. It is essential to be quite clear about 
how, when and where screening should happen to 
ensure effective implementation 
Risk factors for coronary 
heart disease 
• Weight surveillance/case-finding approach in 
primary care 
(CHD)/stroke  
Blood pressure  
Cholesterol  
Smoking cessation  
 
 
Screening in adults is potentially big business. Media interest in health is insatiable, 
and anyone who reads the newspapers, watches television or listens to radio can hardly 
fail to be aware of the various diseases that may be lying in wait for them. Of course, it 
is of benefit if potential health problems can be identified early and treated. But society 
must beware of turning health into an obsession and must resist both the increasing 
medicalization of life and the growing politicization of medicine. 
The national programmes for breast and cervical cancer should be continued but 
kept under review with an emphasis on quality control and on providing balanced and 
understandable information to enable women to make a truly informed choice without 
pressure from health professionals on whether or not to participate. 
A national programme of screening for colorectal cancer by faecal occult blood 
testing in adults aged from 50 to 74 years has been agreed in the United Kingdom and 
on some other European countries but it is essential that adequate diagnostic, treatment 
and follow-up facilities are in place before it is introduced. 
Screening for risk factors of coronary heart disease and stroke should be carried 
out in the primary care setting with advice, treatment and follow-up as appropriate. In 
the case of abdominal aortic aneurysm, it now seems clear that ultrasound screening in 
men aged 65 years and over would reduce mortality from this condition, although the 
benefit for those aged over 75 years has been questioned. As with colorectal cancer, 
however, national implementation should await the certainty that adequate facilities 
and resources are available. In the case of screening for diabetic retinopathy, close 
attention must be paid to audit and the need to be absolutely clear about how, when and 
where to screen. 
 
6. Elderly. 
Society is facing a major challenge in how best to maintain health and quality of life in 
populations where the proportion of people aged over 60 years now outnumbers those 
aged under 16 and the number of individuals aged over 85 is rising. 
A system of regular surveillance and case-finding in primary care would seem to 
be the most appropriate form of screening, particularly in those aged 75 and over, but 
the resource implications of this must be confronted. Several simple tests, such as 
identifying difficulties with sight or hearing or problems with feet, can make a huge 
difference to the comfort and quality of life. Depression is another area where 
identification and treatment could improve well-being. Social and community support 
are also vital in enabling older people to enjoy as independent and contented a life as 
possible. The emphasis in screening at this stage of life should be on improving quality 
of life and preserving function and independence, rather than on providing “heroic” 
treatments to prevent mortality. 
In Table 9, screenings, recommended in Europe in elderly people are presented. 
 
 
Table 9. Recommended screenings in elderly in Europe (4) 
Condition under screening Comment 
Hypertension Physical assessment 
Early heart failure  
Hearing loss  
Vision loss  
Incontinence  
Lack of physical activity  
Foot problems  
Review of medication  
  
Depression Mental assessment 
Alcohol use T 
  
Falls Social assessment 
Undernutrition  
Isolation  
 Conclusions 
Screening programmes and practices vary widely across the countries of the European 
Union (EU). This is inevitable given the differing structures and financing of health 
services, and differing demographic features of the population. There are, however, key 
objectives to strive for. 
These include having one national body per country responsible for practice and 
policy, scrupulous adherence to the long-established screening criteria, accurate population 
registers, greater uniformity of access across different mare as of a given country and 
across different socioeconomic groups, and sound research evidence on which to base 
practice. The wide variation in practice in Europe illustrates the complexity of screening. 
Some lessons, however, stand out. Key points of screening in the EU are (4): 
• antenatal screening programmes for Down syndrome and spina bifida are performed 
only in a few countries and are mainly optional. They are often only recommended to 
women at high risk. 
• neonatal screening for phenylketonuria is systematically recommended in all 
countries belonging to the EU before May 2004, except Finland. 
• breast cancer screening and cervical cancer screening programmes are recommended 
in some European countries. 
• HIV screening is more common among the new Member States and three Candidate 
Countries and covers specific vulnerable groups, such as pregnant women and blood 
donors. 
• TB screening is performed in a few European countries, especially central and 
eastern European countries, such as Hungary, Romania and Turkey. 
• not all the countries follow the basic criteria for screening. A population register to 
allow recall and follow-up of patients is often missing. A single national body for 
reviewing tests and practice is rare. 
 
 
 
CASE STUDY: BREAST CANCER SCREENING 
Cancer screenings 
At present the following screening tests meet requirements for organized screening 
programmes (Council Recommendation of 2 December 2003 on cancer screening 
(2003/878/EC) OJ L 327/34-38) (15): 
• pap smear screening for cervical abnormalities starting at the latest by the age of 30 
and definitely not before the age of 20, 
• mammography screening for breast cancer in women aged 50-69 in accordance with 
European guidelines on quality assurance in mammography, 
• faecal occult blood screening for colorectal cancer in men and women age 50-74.  
 
Decisions on implementation of cancer screening programmes must be made as part of a 
general priority-setting exercise on the use of healthcare resources (16-18). 
Other cancer screening tests are not yet recommended for EU-wide population-based 
cancer screening, although they already may be used in individual screening on demand. 
Such tests may provide individual benefits but at the same time may also lead to adverse 
effects for individuals (e.g. unfounded anxiety) and the public (e.g. additional financial 
burden). Recommendations for such tests cannot be made until they have shown to have 
benefits such  as reducing disease-specific mortality or improving survival (19-21). 
 Potentially promising screening tests currently being evaluated in randomised 
controlled trials, include: 
• prostate-specific antigen (PSA) testing for prostate cancer, 
• mammography screening for women aged 40-49 for breast cancer, 
• immunological Faecal Occult Blood Testing (FOBT) for colorectal cancer, 
• flexible colonoscopy for colorectal cancer. 
 
Once the effectiveness of a new screening test has been demonstrated, evaluation of  
modified testing methods may be possible using intermediate/surrogate endpoints, if the 
positive predictive value of such endpoints is sufficiently established. Some examples of 
screening methods which fall into this category are listed below: 
• any novel alternative tests for faecal occult blood, 
• liquid-based cervical cytology, 
• testing for high risk human papilloma virus (HPV) infection, 
• other novel methods for the preparation or interpretation of cervical specimens. 
 
Any screening test which has been demonstrated to be effective should be offered on a 
population basis only in organised screening programmes, with quality assurance at all 
levels and full information about the benefits and risks (22, 23). 
 
 
Breast cancer screening 
Breast cancer is currently the most frequent cancer and the most frequent cause of cancer 
induced deaths in women in Europe. Demographic trends indicate a continuing increase in 
this substantial public health problem. Systematic early detection through screening, 
effective diagnostic pathways and optimal treatment have the ability to substantially lower 
current breast cancer mortality rates and reduce the burden of this disease in the 
population. 
In order that these benefits may be obtained, high quality services are essential. 
These may be achieved through the underlying basic principles of training, specialisation,  
volume levels, multidisciplinary team working, the use of set targets and 
performance indicators and audit. Ethically these principles should be regarded as applying 
equally to symptomatic diagnostic services and screening. 
The primary aim of a breast screening programme is to reduce mortality from breast 
cancer through early detection. Unnecessary workup of lesions which show clearly benign 
features should be avoided in order to minimise anxiety and maintain a streamlined cost-
effective service. Women attending a symptomatic breast service have different needs and 
anxieties and therefore mixing of screening and symptomatic women in clinics should be 
avoided. 
 
Fundamental points and principles of the European guidelines for 
quality assurance of breast cancer screening programmes 
Fundamental points and principles of the 4th edition of the European guidelines for quality 
assurance of breast cancer screening programmes are (24): 
• breast cancer screening is a complex multidisciplinary undertaking, the objective of 
which is to reduce mortality and morbidity from the disease without adversely 
affecting the health status of participants. It requires trained and experienced 
professionals using up-to-date and specialised equipment; 
• screening usually involves a healthy and asymptomatic population which requires 
adequate information presented in an appropriate and unbiased manner in order to 
allow a fully informed choice as to whether to attend. Information provided must be 
balanced, honest, adequate, truthful, evidence-based, accessible, respectful and 
tailored to individual needs where possible (24-26); 
• mammography remains the cornerstone of population-based breast cancer screening. 
Due attention must be paid to the requisite quality required for its performance and 
interpretation, in order to optimise benefits, lower mortality and provide an adequate 
balance of sensitivity and specificity; 
• physico-technical quality control must ascertain that the equipment used performs at 
a constant high quality level providing sufficient diagnostic information to be able to 
detect breast cancer using as low a radiation dose as is reasonably achievable. 
Routine performance of basic test procedures and dose measurements is essential for 
assuring high quality mammography and comparison between centres; 
• full-field digital mammography can achieve high image quality and is likely to 
become established due to multiple advantages such as image manipulation and 
transmission, data display and future technological developments. Extensive clinical, 
comparative and logistical evaluations are underway; 
• the role of the radiographer is central to producing high quality mammograms which, 
in turn, are crucial for the early diagnosis of breast cancer. Correct positioning of the 
breast on the standard lateral oblique and cranio-caudal views is necessary to allow 
maximum visualisation of the breast tissue, reduce recalls for technical inadequacies 
and maximise the cancer detection rate; 
• radiologists take prime responsibility for mammographic image quality and 
diagnostic interpretation. They must understand the risks and benefits of breast 
cancer screening and the dangers of inadequately trained staff and sub-optimal 
equipment. For quality loop purposes the radiologist performing the screen reading 
should also be involved at assessment of screen detected abnormalities; 
• all units carrying out screening, diagnosis or assessment must work to agreed 
protocols forming part of a local quality assurance (QA) manual, based on national 
or European documents containing accepted clinical standards and published values. 
They should work within a specialist framework, adhering to set performance  
indicators and targets. Variations of practices and healthcare environments 
throughout the member states must not interfere with the achievement of these; 
• a robust and reliable system of accreditation is required for screening and 
symptomatic units, so that women, purchasers and planners of healthcare services 
can identify those breast clinics and units which are operating to a satisfactory 
standard. Any accreditation system should only recognise centres that employ 
sufficiently skilled and trained personnel; 
• the provision of rapid diagnostic clinics where skilled multidisciplinary advice and 
investigation can be provided is advantageous for women with significant breast 
problems in order to avoid unnecessary delay in outline of management planning or 
to permit immediate discharge of women with normal/benign disease; 
• population breast screening programmes should ideally be based within or closely 
associated with a specialised breast unit and share the services of trained expert 
personnel. 
 Key performance indicators for monitoring in population based 
breast cancer screening programme 
Key performance indicators to be monitored in any population based breast cancer 
screening programme are presented in Table 10. 
 
Table 10. Summary table of key performance indicators to be monitored in any 
population based breast cancer screening programme. 
 Performance indicator Acceptable 
level 
Desirable level 
1. Target optical density 1.4 - 1.9 OD 1.4 - 1.9 OD 
2. Spatial resolution > 12 lp/mm > 15 lp/mm 
3. Glandular dose – PMMA thickness at 4.5 cm < 2.5 mGy < 2.0 mGy 
4. Threshold contrast visibility < 1.5% < 1.5% 
5. Proportion of women invited that attend for 
screening 
> 70% > 75% 
6. Proportion of eligible women reinvited within the 
specified screening interval 
> 95% 100% 
7. Proportion of eligible women reinvited within the 
specified screening interval + 6 months 
> 98% 100% 
8. Proportion of women with a radiographically 
acceptable screening examination 
97% > 97% 
9. Proportion of women informed of procedure and 
time scale of receiving results 
100% 100% 
10. Proportion of women undergoing a technical 
repeat screening examination 
< 3% < 1% 
11. Proportion of women undergoing additional 
imaging at the time of the screening examination 
in order to further clarify the mammographic 
appearances 
< 5% < 1% 
12. Proportion of women recalled for further 
assessment 
  
 • initial screening examinations < 7% < 5% 
 • subsequent screening examinations < 5% < 3% 
13. Proportion of screened women subjected to early 
recall following diagnostic assessment 
< 1% 0% 
14. Breast cancer detection rate, expressed as a 
multiple of the underlying, expected, breast cancer 
incidence rate in the absence of screening (IR): 
  
 • initial screening examinations 3 x IR > 3 x IR 
 • subsequent screening examinations 1.5 x IR > 1.5 x IR 
15. Interval cancer rate as a proportion of the 
underlying, expected, breast cancer incidence rate 
in the absence of screening: 
  
 • within the first year (0-11 months) 30% < 30% 
 • within the second year (12-23 months) 
 
50% < 50% 
Table 10. Cont 
 
 Performance indicator Acceptable 
level 
Desirable level 
16. Proportion of screen-detected cancers that are 
invasive 
90% 80-90% 
17. Proportion of screen-detected cancers that are 
stage II+: 
  
 • initial screening examinations NA < 30% 
 • subsequent-regular screening examinations 25% < 25% 
18. Proportion of invasive screen-detected cancers that 
are node-negative: 
  
 • initial screening examinations NA > 70% 
 • subsequent-regular screening examinations 75% > 75% 
19. Proportion of invasive screen-detected cancers that 
are ≤ 10 mm in size 
  
 • initial screening examinations NA ≥ 25% 
 • subsequent-regular screening examinations ≥ 25% ≥ 30% 
20. Proportion of invasive screen-detected cancers that 
are < 15 mm in size 
50% > 50% 
21. Proportion of invasive screen-detected cancers < 
10 mm in size for which there was no frozen 
section 
95% > 95% 
22. Absolute sensitivity of FNAC > 60% > 70% 
23. Complete sensitivity of FNAC > 80% > 90% 
24. Specificity of FNAC > 55% > 65% 
25. Absolute sensitivity of core biopsy > 70% > 80% 
26. Complete sensitivity of core biopsy > 80% > 90% 
27. Specificity of core biopsy > 75% > 85% 
28. Proportion of localised impalpable lesions 
successfully excised at the first operation 
> 90% > 95% 
29. Proportion of image-guided FNAC procedures 
with insufficient result 
< 25% < 15% 
30. Proportion of image-guided FNAC procedures 
from lesions subsequently proven to be malignant, 
with an insufficient result 
< 10% < 5% 
31. Proportion of patients subsequently proven to have 
breast cancer with a pre-operative FNAC or core 
biopsy at the diagnosis of cancer 
90% > 90% 
32. Proportion of patients subsequently proven to have 
clinically occult breast cancer with a pre-operative 
FNAC or core biopsy that is diagnostic for cancer 
70% > 70% 
33. Proportion of image-guided core/vacuum 
procedures 0o0with an insufficient result 
< 20% < 10% 
34. Benign to malignant open surgical biopsy ratio in 
women at initial and subsequent examinations 
≤ 1:2 ≤ 1:4 
Table 10.  Cont. 
Performance indicator Acceptable 
level 
Desirable 
level 
35. Proportion of wires placed within 1 cm of an 
impalpable lesion prior to excision 
90% > 90% 
36. Proportion of benign diagnostic biopsies on 
impalpable lesions weighing less than 30 grams 
90% > 90% 
37. Proportion of patients where a repeat operation is 
needed after incomplete excision 
10% < 10% 
38. Time (in working days) between:   
 • screening mammography and result 15 wd 10 wd 
 • symptomatic mammography and result 5 wd  
 • result of screening mammography and 
offered assessment 
5 wd 3 wd 
 • result of diagnostic mammography and 
offered assessment 
5 wd  
 • assessment and issuing of results 5 wd  
 • decision to operate and date offered for 
surgery 
15 wd 10 wd 
39. Time (in working days) between:   
 • screening mammography and result   
 ≤ 15 wd 95% > 95% 
 ≤ 10 wd 90% > 90% 
 • symptomatic mammography and result   
 ≤ 5 wd 90% > 90% 
 • result of screening mammography and 
offered assessment 
  
 ≤ 5 wd 90% > 90% 
 ≤ 3 wd 70% > 70% 
 • result of symptomatic mammography and 
offered assessment 
  
 ≤ 5 wd 90% > 90% 
 • assessment and issuing of results   
 ≤ 5 wd 90% > 90% 
 • decision to operate and date offered for 
surgery 
  
 ≤ 15 wd 90% > 90% 
 ≤ 10 wd 70% > 70% 
LEGEND: OD=optical density, PMMA=test object material (polymethylmethacrylate), 
IR=incidence rate, NA=not applicable, FNAC=fine needle aspiration citology, wd= week 
days 
 
 
 
 
 
EXERCISES 
Task 1 
Carefully read the theoretical background of this module, and recommended readings.  
 
Task 2 
Critically discuss the differences between population based and opportunistic screening. 
 
Task 3 
Name the basic criteria to be fulfilled before screening for any condition is introduced. 
 
Task 4 
How do we describe the validity of screening test? Describe an example. 
 
Task 5 
List some advantages and disadvantages of the screening. 
 
Task 6 
Which screening tests for cancer meet all requirements for organized screening 
programmes. 
 
Task 7 
Critically assess the advantages and disadvantages of a population based breast cancer 
screening programme. 
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